The number of notified cases of invasive pneumococcal disease (IPD) in the third quarter of 2018 was greater than the previous quarter, but lower than the third quarter of 2017. Following the July 2011 replacement of the 7-valent pneumococcal conjugate vaccine (7vPCV) in the childhood immunisation program with the 13-valent pneumococcal conjugate vaccine (13vPCV), there was an initial relatively rapid decline in disease due to the additional six serotypes covered by the 13vPCV across all age groups, however more recently this decline is no longer evident. Over this period the number of cases due to the eleven serotypes additionally covered by the 23-valent pneumococcal polysaccharide vaccine (23vPPV) and also those serotypes not covered by any available vaccine has been increasing steadily across all age groups ( Figure 1 ).
and the third quarter of 2017 (47%; 34/72) (Figure 2 ). The most frequent serotypes among cases aged less than 5 years this quarter were serotype 19F (16%; 12/73) and 3 (15%; 11/73), both of which are included in the 13vPCV. Of the 33 cases aged less than 5 years with 13vPCV serotypes, 24 cases were fully vaccinated and considered to be 13vPCV failures. These 13vPCV failures were due to serotypes 3 (n=8), 19F (n=8), 19A (n=6) and 14 (n=2) ( Table 4) .
Among Indigenous Australians aged 50 years and over, there were 35 cases of IPD reported this quarter. Although the number of reported cases of IPD in this population group this quarter were almost two times higher compared with the previous quarter (n=18), they were similar to the number of cases reported in the third quarter of 2017 (n=33). Of those cases with a reported serotype (n=32), 25 (78%) were due to a serotype included in the 23vPPV (Figure 3 ).
Whilst the proportion of cases with a reported serotype that were due to a serotype included in the 23vPPV is similar to the proportion reported last quarter (81%; 13/16), this proportion is much higher compared with the third quarter of 2017 (56%; 18/32). Amongst this population group, the most frequently reported serotypes this quarter were serotypes 3 (n=7), 8 (n=4) and 17F (n=4), all of which are included in the 23vPPV.
Among non-Indigenous Australians
ii aged 65 years and over there were 306 cases of IPD reported this quarter. The number of notified cases of IPD in this population group were 57% higher compared to the number of cases reported in the previous quarter (n=195) and 11% lower than the number reported in the third quarter of 2017 (n=342). Of those cases with a reported serotype (n=281), 63% (177/281) were due to a serotype included in the 23vPPV ( Figure   4 ). This was higher than the proportion in the previous quarter (55%; 103/186) and similar to the third quarter of 2017 (62%; 207/332). For this quarter, serotype 3 (n=42) was the most common serotype reported for this population group, followed by serotypes 9N (n=25), 6C (n=22) and 22F (n=22). Serotypes 3 and 22F are included in the 23vPPV.
During this quarter there were 51 deaths attributed to a variety of IPD serotypes. Forty-one (81%) of the cases had a serotype covered by currently available pneumococcal vaccines, eight were due to a non-vaccine serotype, and two were reported as being untyped. Four (8%) of the reported deaths this quarter were reported in Indigenous
Australians. The median age of those cases reported to have died this quarter was 71 years (range 0 to 98 years).
ii Non-Indigenous Australians includes cases reported with an Indigenous status of non-Indigenous, not stated, blank or unknown. 
Notes
The data in this report are provisional and subject to change as laboratory results and additional case information become available. More detailed data analysis of IPD in Australia and surveillance methodology are described in the IPD annual report series published in Communicable Diseases Intelligence.
In Australia, pneumococcal vaccination is recommended as part of routine immunisation for children, individuals with specific underlying conditions associated with increased risk of IPD and older Australians. More information on the scheduling of the pneumococcal vaccination can be found on the Immunise Australia Program website (www.immunise.health.gov.au).
In this report, a 'vaccine failure' is reported when a child aged less than 5 years is diagnosed with IPD due to a serotype found in the 13vPCV and they have received 3 primary scheduled doses of 13vPCV at least 2 weeks prior to disease onset with at least 28 days between doses of vaccine.
There are 3 pneumococcal vaccines available in Australia, each targeting multiple serotypes ( Table 5 ). Note that in this report serotype analysis is generally grouped according to vaccine composition.
Follow-up of all notified cases of IPD is undertaken in all states and territories except New South Wales and Victoria who conduct targeted follow-up of notified cases aged under 5 years, and 50 years or over for enhanced data. Followup of notified cases of IPD in Queensland is undertaken in all areas except Metro South and Gold Coast Public Health Units who conduct targeted follow-up of notified cases for those aged under 5 years only. However, in these areas where targeted case follow-up is undertaken, some enhanced data may also be available outside these targeted age groups. 
